You are here:

New guidance for Patient Group Partners taking part in SMC Committee meetings

From June 2017 we will be introducing new processes to improve how we involve patient groups in our committee meetings. 

The new processes, which will see patient groups actively involved in the relevant parts of our committee meetings, aim to enhance the quality of discussion and decision making. The changes follow on from the publication of the review into access to new medicines in December 2016. 

The new processes will initially be introduced for medicines being considered through our Patient and Clinician Engagement (PACE) process, for medicines used to treat end of life and very rare conditions. Following a trial period, the new process will be rolled out to cover all medicines in autumn 2017. 

Find out more about Patient Group Partner participation in SMC Committee meetings